BridgeBio Pharma (BBIO) Treasury Shares (2017 - 2026)

BridgeBio Pharma's Treasury Shares history runs 7 years deep, the most recent figure standing at $405.8 million for Q1 2026.

• In Q1 2026, Treasury Shares rose 25.52% year-over-year to $405.8 million; the TTM figure through Mar 2026 stood at $405.8 million (up 25.52% YoY), while the FY2025 annual figure was $323.3 million, up 17.55% from the prior year.
• Treasury Shares came in at $405.8 million for Q1 2026 at BridgeBio Pharma, up from $323.3 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $12.8 million in Q1 2025 to a low of $218934.0 in Q3 2023.
• A 5-year average of $6.2 million and a median of $6.2 million in 2022 frame the typical range for Treasury Shares.
• On a YoY basis, Treasury Shares climbed as much as 120.0% in 2022 and fell as far as 0.0% in 2022.
• BridgeBio Pharma's Treasury Shares stood at $275.0 million in 2022, then changed by 0.0% to $275.0 million in 2023, then changed by 0.0% to $275.0 million in 2024, then climbed by 17.55% to $323.3 million in 2025, then increased by 25.52% to $405.8 million in 2026.
• According to Business Quant data, Treasury Shares over the past three periods registered $405.8 million, $323.3 million, and $323.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison